Prostate News Archive
17-Jul-2009
A Better Blood Test For Prostate Cancer (Medical News Today)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. Current standards of screening and testing for prostate cancer focus on the blood protein prostate-specific antigen (PSA) along with a digital rectal examination. [click ... EPCA-2 testing more accurate way to identify cancer in the prostate (News-Medical-Net)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. Cesium-131 From IsoRay Medical (TM), Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer ... (Business Wire via Yahoo! Finance)
CHICAGO----Investigators of a recent multi-institutional trial, led by principal investigator Bradley Prestidge, conclude that Cesium-131, a medical isotope used in low dose brachytherapy treatment for prostate cancer, "... has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners." For Men, a Saving Surgery: Twenty-Five Years Ago, Patrick C. Walsh Devised a Prostate-Cancer Operation That Allowed ... (RedNova)
By Marie McCullough, The Philadelphia Inquirer Apr. 30--In 1982, the surgical cure for prostate cancer was considered worse than the disease. Removing the prostate meant life-threatening bleeding, guaranteed impotence, and a 1 in 4 chance of incontinence.
Back to Prostate News Archive
